Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rezolute, Inc. (Nasdaq: RZLT) SEC filings page provides access to the company’s regulatory disclosures as a publicly traded, late-stage rare disease company focused on hypoglycemia caused by hyperinsulinism. Through these documents, investors can review how Rezolute reports on its clinical programs, financial condition, governance and shareholder matters.
Current reports on Form 8-K include items such as clinical and business updates, financial results, and corporate actions. For example, recent 8-K filings reference press releases on quarterly and annual financial results, alignment with the U.S. Food and Drug Administration on the design of the Phase 3 upLIFT study in tumor hyperinsulinism, and updates on the ersodetug development program. Other 8-Ks describe material agreements, executive appointments, amendments to employment arrangements, and the termination of an at-the-market equity program.
Proxy materials, such as the definitive proxy statement on Schedule DEF 14A, outline proposals presented at Rezolute’s annual meeting of stockholders. These include the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, amendments to the company’s equity incentive plan, and potential adjournment proposals. Related 8-K filings report the final voting results for these matters.
Investors can also use this page to locate filings that incorporate press releases on financial results, which provide additional context on research and development spending, general and administrative expenses, and net loss figures, as described by the company. While this page focuses on accessing the underlying SEC documents, AI-powered tools on the platform can help summarize key points from lengthy filings, highlight important sections, and make it easier to understand Rezolute’s disclosures on clinical progress, compensation policies and capital structure.
Together, these SEC filings form an official record of Rezolute’s activities as a Nasdaq-listed issuer developing its lead monoclonal antibody therapy, ersodetug, for congenital and tumor hyperinsulinism.
Rezolute Inc. received an updated ownership filing from FMR LLC and Abigail P. Johnson. The Schedule 13G/A (Amendment No. 2) reports beneficial ownership of 2,305,568 shares of Rezolute common stock, representing 2.5% of the outstanding class as of the reported date. FMR LLC is identified as a parent holding company, and Abigail P. Johnson is listed as an individual reporting person with sole dispositive power over the same 2,305,568 shares.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Rezolute. It also notes that one or more other persons have rights to receive dividends or sale proceeds from these shares, but no other person holds more than 5% of the common stock.
Rezolute, Inc. furnished an update focused on its sunRIZE clinical trial and early access program for tumor hyperinsulinism (HI). The company issued a press release providing further insights into the sunRIZE trial, a cumulative table summarizing data from the initial nine tumor HI participants in its expanded access program, and an updated corporate presentation deck.
These materials, furnished as Exhibits 99.1, 99.2 and 99.3, include patient characteristics, ersodetug dosing information and observed outcomes for the early participants, as well as broader corporate information. The company states that this information is being furnished rather than filed under the Exchange Act, which limits how it is treated for certain liability and incorporation-by-reference purposes.
Rezolute, Inc. director Wladimir Hogenhuis reported an open-market purchase of company stock. On 12/16/2025, he bought 5,650 Rezolute common shares at a price of $1.69 per share, coded as a purchase transaction. Following this trade, he beneficially owns 119,675 common shares in a direct ownership position.
Rezolute, Inc.'s Chief Medical Officer reported buying additional company stock. On 12/16/2025, the officer purchased 28,000 common shares of Rezolute at a price of $1.7 per share. After this transaction, the officer beneficially owned 308,352 common shares directly and 15,500 common shares indirectly through an IRA. This filing highlights increased personal exposure of a senior executive to Rezolute’s equity.
Rezolute, Inc. Chief Financial Officer Daron Evans reported open-market purchases of company stock. On December 15, 2025, he bought 40,000 common shares at a weighted average price of $1.766, in transactions within a range of $1.65 to $1.81. He also reported purchases of 2,500 shares each for two minor children at weighted average prices of $1.785 and $1.79.
Following these transactions, Evans directly owns 415,900 common shares. He also reports indirect beneficial ownership of shares held for three minor children, his spouse, and 40,000 shares held by PoC Capital LLC, a California limited liability company he manages, while disclaiming beneficial ownership of those LLC-held shares beyond his pecuniary interest.
Rezolute, Inc. CEO and director Nevan C. Elam reported purchasing 32,000 common shares of Rezolute on 12/15/2025 at $1.59 per share. Following this transaction, his direct beneficial ownership increased to 641,119 Rezolute common shares.
Rezolute, Inc. insider Sunil Patilal Karnawat, the company’s Chief Commercial Officer, reported open-market purchases of common stock. On 12/15/2025, he bought 12,000 common shares at $1.6199 per share and an additional 100 common shares at $1.6 per share. Following these transactions, he directly owns 71,542 Rezolute common shares, with another 8,000 shares held in an individual retirement account and 1,898 shares held in a health savings account.
Rezolute, Inc. (RZLT) reported an equity award to its Chief Medical Officer, Brian Kenneth Roberts, in a Form 4 filing. On 11/19/2025, he received 123,000 restricted stock units (RSUs)$0. These RSUs vest annually over three years, with the first portion vesting on
On the same date, he was also granted an employee stock option covering 72,000 common shares at an exercise price of
Rezolute, Inc. (RZLT) reported an equity award to its Chief Commercial Officer. On November 19, 2025, the officer received 32,000 common shares in the form of restricted stock units, granted at a price of $0. After this transaction, the officer held 59,442 common shares directly, plus 8,000 shares in an individual retirement account and 1,898 shares in a health savings account.
The filing also shows a new employee stock option grant for 19,000 options with an exercise price of $10.16 per share, expiring on November 19, 2035. The restricted stock units vest annually over three years starting on December 1, 2026, while the options vest in equal monthly installments over 36 months beginning on December 19, 2025.
Rezolute, Inc. reported new equity awards to its CEO and director, Nevan C. Elam. On 11/19/2025, he received 317,000 common shares as restricted stock units at a price of $0, increasing his beneficial ownership to 609,119 common shares held directly.
He also received an employee stock option to buy 186,000 common shares at an exercise price of $10.16 per share. These options are exercisable through 11/19/2035. The restricted stock units vest annually over three years starting on December 1, 2026, and the options vest in equal monthly installments of 1/36 beginning on December 19, 2025.
FAQ
What is the current stock price of Rezolute (RZLT)?
What is the market cap of Rezolute (RZLT)?
